"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
Descriptor ID |
D007004
|
MeSH Number(s) |
D27.505.696.422
|
Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 1 | 2 |
1996 | 1 | 0 | 1 |
1997 | 3 | 3 | 6 |
1998 | 1 | 3 | 4 |
1999 | 0 | 2 | 2 |
2000 | 3 | 3 | 6 |
2001 | 1 | 3 | 4 |
2002 | 4 | 2 | 6 |
2003 | 3 | 2 | 5 |
2004 | 4 | 1 | 5 |
2005 | 5 | 3 | 8 |
2006 | 5 | 4 | 9 |
2007 | 3 | 4 | 7 |
2008 | 5 | 3 | 8 |
2009 | 4 | 6 | 10 |
2010 | 2 | 5 | 7 |
2011 | 5 | 5 | 10 |
2012 | 3 | 2 | 5 |
2013 | 7 | 7 | 14 |
2014 | 10 | 7 | 17 |
2015 | 11 | 6 | 17 |
2016 | 6 | 2 | 8 |
2017 | 10 | 4 | 14 |
2018 | 4 | 9 | 13 |
2019 | 9 | 10 | 19 |
2020 | 2 | 5 | 7 |
2021 | 1 | 11 | 12 |
2022 | 2 | 4 | 6 |
2023 | 0 | 4 | 4 |
2024 | 6 | 6 | 12 |
2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Res Care. 2025 Apr 23; 13(2).
-
GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngol Head Neck Surg. 2025 Mar 01; 151(3):243-252.
-
Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies. Lancet Diabetes Endocrinol. 2025 05; 13(5):427-437.
-
Deprescribing in Older Adults With Type 2 Diabetes: Associations With Patients' Perspectives: The Diabetes and Aging Study. J Am Geriatr Soc. 2025 Apr; 73(4):1155-1167.
-
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol. 2025 Jan; 19(1):191-216.
-
Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
-
Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population. Diabetes Obes Metab. 2024 Nov; 26(11):5261-5271.
-
Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease. AAPS J. 2024 08 19; 26(5):94.
-
Expanding Clinical Use of Sodium-glucose Cotransporter-2 Inhibitors? J Cardiothorac Vasc Anesth. 2024 Oct; 38(10):2135-2138.
-
CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis. Front Endocrinol (Lausanne). 2024; 15:1359780.